Press release content from Globe Newswire. The AP news staff was not involved in its creation.
New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases
CENTOGENE GmbHMay 6, 2021 GMT
Database has grown to more than 465,000 analyzed patients, with more than 225,000 being linked to HPO terms
Release includes increase of almost 19 million to over 31 million unique variants
New features, including variant classification based on ACMG guidelines and streamlined HPO search tools, help to accelerate diagnosis and expand on resources for orphan drug development
New biochemistry module expands on previous genetic testing foundation to further fuel the knowledge base of rare diseases
HPO source code released for free use globally
Published: Mar 09, 2021
Rostock International Parkinson s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
Significant milestone of 10,000 participants reached
With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson s Disease (ROPAD) Study, with the recruitment and genetic testing of 10,000 participants. Including more than 120 study sites around the world, CENTOGENE is leading the largest study of its kin
CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study
March 09, 2021 06:30 ET | Source: CENTOGENE GmbH CENTOGENE GmbH Rostock, GERMANY
Rostock International Parkinson s Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease progression, diagnosis, and treatment
Significant milestone of 10,000 participants reached
With over 120 study sites around the world, CENTOGENE is leading the largest corresponding study for genetics in Parkinson’s disease ever performed
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinson
CENTOGENE Announces Voting Results of Extraordinary General Meeting wboc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wboc.com Daily Mail and Mail on Sunday newspapers.
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2020 Centogene N.V. (Nasdaq: CNTG) (“CENTOGENE” or the “Company”), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today provided an update on its corporate progress and reported its financial results for the three and nine months ended September 30, 2020.
Revenues increased 212% compared to Q3 2019, driven by the continued expansion of our COVID-19 testing offering
Increased 2020 full-year revenue guidance to more than €100 million